TOP TEN perturbations for 1553314_a_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1553314_a_at
Selected probe(set): 1553314_a_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1553314_a_at (1553314_a_at) across 6673 perturbations tested by GENEVESTIGATOR:

small cell lung cancer study 4 (1. gen. PDX) / small cell lung cancer study 4 (XCL from PDX)

Relative Expression (log2-ratio):2.8784428
Number of Samples:4 / 3
Experimental small cell lung cancer study 4 (1. gen. PDX)
A small cell lung cancer (SCLC) primary xenograft tumor tissue samples derived from three chemo-naive patients (LX22; LX33 and LX36; first generation-1. gen.). The discarded tissue obtained during bronchoscopy of SCLC patients was used to generate a xenograft. Aseptically resuspended tumour cells were injected s.c. in the flanks of nonobese diabetic/severe combined immunodeficient mice (NOD/SCID). The mice were sacrificed when the P0 tumors reached 1cm in diameter.
Control small cell lung cancer study 4 (XCL from PDX)
Xenograft-derived cell lines (XCL) established from a small cell lung carcinoma (SCLC) patient derived xenografts (PDX). The discarded tissue from three chemo-naive patients (LX22; LX33 and LX35) was obtained during bronchoscopy and used to generate a xenograft. Aseptically resuspended tumour cells were injected s.c. in the flanks of nonobese diabetic/severe combined immunodeficient mice. The mice were sacrificed when the P0 tumors reached 1cm in diameter. Obtained cells were used for conventional cell culture cultivation.

small cell lung cancer study 4 (2. gen. PDX) / small cell lung cancer study 4 (1. gen. PDX)

Relative Expression (log2-ratio):-2.227871
Number of Samples:4 / 4
Experimental small cell lung cancer study 4 (2. gen. PDX)
Xenografts (secondary) tumor tissue samples derived from a PDX-derived cell lines. A patient derived xenograft (PDX)-derived cell lines were grown under conventional tissue culture conditions for six months and then reimplanted to generate secondary xenografts (2. gen.).
Control small cell lung cancer study 4 (1. gen. PDX)
A small cell lung cancer (SCLC) primary xenograft tumor tissue samples derived from three chemo-naive patients (LX22; LX33 and LX36; first generation-1. gen.). The discarded tissue obtained during bronchoscopy of SCLC patients was used to generate a xenograft. Aseptically resuspended tumour cells were injected s.c. in the flanks of nonobese diabetic/severe combined immunodeficient mice (NOD/SCID). The mice were sacrificed when the P0 tumors reached 1cm in diameter.

rheumatoid arthritis study 37 (pbCD8ememTC) / normal peripheral blood CD8 effector memory T-cell sample

Relative Expression (log2-ratio):-2.112255
Number of Samples:6 / 6
Experimental rheumatoid arthritis study 37 (pbCD8ememTC)
Peripheral blood CD8 effector memory T-cell samples derived from patients with rheumatoid arthritis (RA). Some of the patients were assigned to the treatment with disease-modifying antirheumatic drugs (DMARDs) i.e. tocilizumab (TCZ) and/or infliximab (IFX) and/or methotrexat (MTX). Patients characteristics: age 46.50±16.50 year; 2 males and 4 females; RF positive 5 (83.3%); ACPA positive 4 (66.7%); CRP 1.45±1.12 mg/dl; ESR 54.67±41.91 mm/hr; DAS28-CRP 4.86±0.69; DAS28-ESR 5.60±1.07; SDAI 25.12±8.82; CDAI 23.67±9.13; HAQ-DI 0.75±0.47; TJC28 7.33±2.66; SJC28 6.50±3.62; Pain, VAS 55.00±23.42; Physician GA, VAS 41.50 ±13.50 mm; Subject GA, VAS 56.83±20.68 mm
Control normal peripheral blood CD8 effector memory T-cell sample
Peripheral blood CD8 effector memory T-cell samples derived from healthy control subjects who did not have autoimmune diseases or were not receiving any drugs. Donor characteristics: age 43.83±6.55 year; 6 females.

Merkel cell carcinoma study 3 (metastatic) / normal skin tissue

Relative Expression (log2-ratio):2.0336437
Number of Samples:11 / 64
Experimental Merkel cell carcinoma study 3 (metastatic)
Metastatic tumor tissue from different metastatic sites (skin, lymph node, parotid gland) of patients with Merkel cell carcinoma of the skin.
Control normal skin tissue
Normal skin samples from healthy donors.

Merkel cell carcinoma study 3 (primary) / skin squamous cell carcinoma study 6

Relative Expression (log2-ratio):1.8139324
Number of Samples:19 / 4
Experimental Merkel cell carcinoma study 3 (primary)
Primary tumor tissue from the skin of patients with Merkel cell carcinoma.
Control skin squamous cell carcinoma study 6
Primary tumor tissue from the skin of patients with squamous cell carcinoma (SCC).

Merkel cell carcinoma study 3 (primary) / normal skin tissue

Relative Expression (log2-ratio):1.756691
Number of Samples:19 / 64
Experimental Merkel cell carcinoma study 3 (primary)
Primary tumor tissue from the skin of patients with Merkel cell carcinoma.
Control normal skin tissue
Normal skin samples from healthy donors.

Merkel cell carcinoma study 3 (primary) / basal cell carcinoma study 2

Relative Expression (log2-ratio):1.7254143
Number of Samples:19 / 2
Experimental Merkel cell carcinoma study 3 (primary)
Primary tumor tissue from the skin of patients with Merkel cell carcinoma.
Control basal cell carcinoma study 2
Primary tumor tissue from the skin of patients with basal cell carcinoma (BCC).

rheumatoid arthritis study 37 (pbCD8cmemTC) / normal peripheral blood CD8 central memory T-cell sample

Relative Expression (log2-ratio):-1.6677246
Number of Samples:6 / 6
Experimental rheumatoid arthritis study 37 (pbCD8cmemTC)
Peripheral blood CD8 central memory T-cell samples derived from patients with rheumatoid arthritis (RA). Some of the patients were assigned to the treatment with disease-modifying antirheumatic drugs (DMARDs) i.e. tocilizumab (TCZ) and/or infliximab (IFX) and/or methotrexat (MTX). Patients characteristics: age 46.50±16.50 year; 2 males and 4 females; RF positive 5 (83.3%); ACPA positive 4 (66.7%); CRP 1.45±1.12 mg/dl; ESR 54.67±41.91 mm/hr; DAS28-CRP 4.86±0.69; DAS28-ESR 5.60±1.07; SDAI 25.12±8.82; CDAI 23.67±9.13; HAQ-DI 0.75±0.47; TJC28 7.33±2.66; SJC28 6.50±3.62; Pain, VAS 55.00±23.42; Physician GA, VAS 41.50 ±13.50 mm; Subject GA, VAS 56.83±20.68 mm
Control normal peripheral blood CD8 central memory T-cell sample
Peripheral blood CD8 central memory T-cell samples derived from healthy control subjects who did not have autoimmune diseases or were not receiving any drugs. Donor characteristics: age 43.83±6.55 year; 6 females.

stem cell differentiation study 59 (8d) / normal embryonic stem cell sample (WA09)

Relative Expression (log2-ratio):1.4747534
Number of Samples:4 / 4
Experimental stem cell differentiation study 59 (8d)
WA09 embryonic stem cell samples differentiated for 8 days. Further details are described in the paper.
Control normal embryonic stem cell sample (WA09)
Undifferentiated WA09 embryonic stem cell samples.

rheumatoid arthritis study 37 (pbCD4ememTC) / normal peripheral blood CD4 effector memory T-cell sample

Relative Expression (log2-ratio):-1.4179573
Number of Samples:6 / 6
Experimental rheumatoid arthritis study 37 (pbCD4ememTC)
Peripheral blood CD4 effector memory T-cell samples derived from patients with rheumatoid arthritis (RA). Some of the patients were assigned to the treatment with disease-modifying antirheumatic drugs (DMARDs) i.e. tocilizumab (TCZ) and/or infliximab (IFX) and/or methotrexat (MTX). Patients characteristics: age 50.33±21.81 year; 2 males and 4 females; RF positive 6 (100.0%); ACPA positive 5 (83.3%); CRP 2.15±2.05 mg/dl; ESR 58.67±47.83 mm/hr; DAS28-CRP 5.32±1.11; DAS28-ESR 6.01±1.48; SDAI 32.77±16.93; CDAI 30.62±15.61; HAQ-DI 1.15±0.90; TJC28 9.83±5.53; SJC28 9.67±6.25; Pain, VAS 58.33±23.64; Physician GA, VAS 52.50 ±25.64 mm; Subject GA, VAS 58.67±21.18 mm
Control normal peripheral blood CD4 effector memory T-cell sample
Peripheral blood CD4 effector memory T-cell samples derived from healthy control subjects who did not have autoimmune diseases or were not receiving any drugs. Donor characteristics: age 43.33±5.72 year; 6 females.